Humatica advises Intermediate Capital Group (ICG) on their investment in Lucid Group

ndetails

Humatica, the leading private equity specialist advisor for portfolio organisational effectiveness, has advised private equity firm Intermediate Capital Group (ICG) on its investment in Lucid Group.

Founded in 2007, Lucid Group is a strategic healthcare communications company committed to advancing patient health outcomes through healthcare communications that improve the way patients and diseases are managed, and medicines are used. Lucid Group’s pioneering approaches have received industry-wide recognition and have consistently led to above industry growth.

With offices in the UK, US and Asia, Lucid now employs around 250 people. Lucid works in partnership with the world’s leading pharmaceutical and biotech organisations and has played a pivotal role in providing healthcare communication solutions for many of the industry’s innovative blockbuster assets.

Humatica was engaged by ICG to provide Organisational Due Diligence advice for this transaction.

Patrick Mina, Managing Partner UK of Humatica, commented:

“We were delighted to support ICG with pre-deal stage Organisational Due Diligence on Lucid where we helped to identify areas of focus for the value creation plan. We are proud to have assisted ICG on this transaction and look forward to supporting their growth plans in the future.”

Peter Kirtley, ICG’s Managing Director, added:

“ICG is a leading global alternative asset manager, with a long and successful track record of providing capital to support founder-led growing businesses like Lucid Group. We have admired Lucid Group and its reputation within the industry for many years. Through our partnership, together, we can leverage Lucid’s ambition and our sector expertise to build a truly global healthcare communications organisation.”

The Humatica team was led by Patrick Mina, Managing Partner UK and Head of the London office, supported by Humatica Directors Valentina Pozzobon and Andreas Knobloch.

To download the news release in PDF format, click here.

Related News

Humatica 2024 in Review and Outlook 2025
17 Dec, 2024 By Humatica

Humatica 2024 in Review and Outlook 2025

2024 was a milestone year for private equity, and for Humatica. The industry is under greater pressure to generate acceptable returns than ever before. With…

Read more arrowicon
Humatica Expands to the US  with Russell Raath nominated as Operating Partner
28 Nov, 2024 By Humatica

Humatica Expands to the US with Russell Raath nominated as Operating Partner

We are pleased to announce Humatica’s expansion in the United States following a long history of successful project delivery there from Europe. This marks a…

Read more arrowicon
Unlocking PE Value Through Organizational Effectiveness: Highlights from PE Insights DACH Conference
28 Oct, 2024 By Humatica

Unlocking PE Value Through Organizational Effectiveness: Highlights from PE Insights DACH Conference

Humatica’s Andros Payne provided expert insights into leveraging organizational effectiveness for value creation at this year’s Private Equity Insights DACH Conference in Munich. Leaders play…

Read more arrowicon

Subscribe to our Monthly Newsletter and other News Updates

Receive our news and valuable perspectives on organizational effectiveness each month.